NasdaqGM - Nasdaq Real Time Price USD

ArriVent BioPharma, Inc. (AVBP)

21.25

+0.25

+(1.19%)

At close: May 30 at 4:00:01 PM EDT

21.25

0.00

(0.00%)

After hours: May 30 at 4:20:01 PM EDT

Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 17 days ago

AVBP
+1.19%
ArriVent BioPharma Reports First Quarter 2025 Financial Results

Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma,

GlobeNewswire 19 days ago

AVBP
+1.19%
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and

GlobeNewswire last month

AVBP
+1.19%
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ArriVent BioPharma, Inc. (NASDAQ:AVBP) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever-changing environment. Short squeeze is among the […]

Insider Monkey 2 months ago

AVBP
+1.19%
ArriVent BioPharma Reports Full Year 2024 Financial Results

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib in first-line NSCLC harboring EGFR exon 20 insertion mutations achieved target enrollmentSelected next-generation ADC candidate ARR-002 for IND enabling studiesCash and cash equivalents of $266.5 million as of December 31, 2024 NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent Bi

GlobeNewswire 2 months ago

AVBP
+1.19%
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $39 from $36 and keeps a Buy rating on the shares after the company entered into an exclusive license agreement with Lepu Biopharma. The firm says ArriVent’s portfolio continues to broaden with the MRG007 license. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on AVBP: ArriVent BioPharma Expands Oncology

TipRanks 4 months ago

AVBP
+1.19%
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancersFirst Investigational New Drug (IND) submission planned for 1H 2025Expands ArriVent’s growing pipeline of next-generation ADCs NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biophar

GlobeNewswire 4 months ago

AVBP
+1.19%
ArriVent BioPharma Reports Third Quarter 2024 Financial Results

Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash equivalents of $282.9 million as of September 30, 2024 NEWTOWN SQUARE, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to a

GlobeNewswire 6 months ago

AVBP
+1.19%
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or

GlobeNewswire 8 months ago

AVBP
+1.19%
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 8 months ago

AVBP
+1.19%
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 9 months ago

AVBP
+1.19%
ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC) ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC in conjunction with 2024 WCLC on September 9, 2024 at 4:30pm ET Entered into a multi-target antibody drug conjugate (ADC) collaborati

GlobeNewswire 9 months ago

AVBP
+1.19%
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session First prospectively designed randomized clinical data for a small-molecule EGFR tyrosine kinase inhibitor in PACC mutant non-small cell lung cancer patient population ArriVent to host virtual webinar in conjunction with 2024 WCLC NEWTOWN SQUARE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated

GlobeNewswire 9 months ago

AVBP
+1.19%
ArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19%

Key Insights Given the large stake in the stock by institutions, ArriVent BioPharma's stock price might be vulnerable...

Simply Wall St. 9 months ago

AVBP
+1.19%
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise Upfront and milestone payments to Alphamab worth up to $615.5 million for potential ADCs SUZHOU, China and NEWTOWN SQUARE, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., (“ArriVent”) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today anno

GlobeNewswire 11 months ago

AVBP
+1.19%

Performance Overview

Return	AVBP	S&P 500 (^GSPC)
YTD	-20.23%	+0.51%
1-Year	+9.20%	+12.92%
3-Year	-11.46%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ArriVent BioPharma, Inc. (AVBP)

Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Deliver On Growth Plans?

ArriVent BioPharma Reports First Quarter 2025 Financial Results

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts

ArriVent BioPharma Reports Full Year 2024 Financial Results

ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19%

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Performance Overview